Knowthestock.com
BDX - Becton, Dickinson & Co.
SNP 500

Sell

Moderate Growth but DecliningStock Price Very High

48%

based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is -1.11%
Operating Income Growth is -39.8%
Net Income Growth is 4.99%
Earnings Per Share (EPS) Growth is -1.05%
Net Margin is 5.1%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.45
Debt Ratio is 0.21
Current Debt to Net Income Ratio is 5.88
Total Debt to Total Assets Ratio is 0.35
Cash Flow is MODERATE
Cash from Operations Growth is 5.02%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Becton, Dickinson & Co. (BDX) - http://www.bd.com
Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.
Exchange - New York Stock Exchange
Industry - Medical Specialties
Sector - Health Technology
CEO - Thomas E. Polen
Employees - 70,093
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.